Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients

被引：0

作者：

Balamurgan, R. ^{[1
]}

Mohan, B. ^{[2
]}

Kodgule, R. ^{[3
]}

Tandon, M. ^{[3
]}

Pendse, A. ^{[4
]}

Khaladkar, K. ^{[5
]}

Sharath, R. ^{[5
]}

Katare, S. ^{[5
]}

Suryawanshi, S. ^{[5
]}

Barkate, H. ^{[5
]}

机构：

[1] Kovai Diabet Specialty Ctr & Hosp, Diabetol, Coimbatore, Tamil Nadu, India

[2] Brij Med Ctr Pvt Ltd, Diabetol, Kanpur, Uttar Pradesh, India

[3] Glenmark Pharmaceut Ltd, Dept Clin Dev, Mumbai, Maharashtra, India

[4] Glenmark Pharmaceut Ltd, Dept Clin Operat, Mumbai, Maharashtra, India

[5] Glenmark Pharmaceut Ltd, Dept Global Med Affairs, Mumbai, Maharashtra, India

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2022年 / 186卷

关键词：

D O I：

10.1016/j.diabres.2022.109517

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IDF21-0338

引用

页数：1

共 50 条

[1] Real world assessment of effectiveness and safety of FDC of remogliflozin etabonate and Vildagliptin in T2DM patients
Bhattacharyya, S.
Katare, S.
Khaladkar, K.
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
[2] Phase 3 Results of Fixed -Dose Combination of Remogliflozin Etabonate and Vildagliptin in Indian T2DM Patients
Mohan, Brij
Chawla, Manoj S.
Kodgule, Rahul R.
Tandon, Monika
Katare, Sagar
Suryawanshi, Sachin
Barkate, Hanmant V.
[J]. DIABETES, 2021, 70
[3] A real-world clinical experience on effectiveness of remogliflozin etabonate in management of Indian patients with T2DM
Mahapatra, H.
Dalai, S.
Sahoo, A.
Khuntia, M.
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
[4] Combination Therapy of Canagliflozin and Teneligliptin in Japanese Patients with T2DM: Results from Phase 3 Studies
Kaku, Kohei
Kadowaki, Takashi
Inagaki, Nobuya
Kondo, Kazuoki
Nishimura, Kenichi
Kaneko, Genki
Maruyama, Nobuko
Nakanishi, Nobuhiro
Iijima, Hiroaki
Watanabe, Yumi
Goda, Maki
[J]. DIABETES, 2017, 66 : A319 - A319
[5] T2DM treatment trial results
Claire Greenhill
[J]. Nature Reviews Endocrinology, 2019, 15 : 499 - 499
[6] Remogliflozin in Indian T2DM Patients: A Real-World Study
Bhattacharya, Supratik
Katare, Sagar
[J]. DIABETES, 2020, 69
[7] T2DM treatment trial results
Greenhill, Claire
[J]. NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (09) : 499 - 499
[8] First Human Dose Escalation Study with Remogliflozin Etabonate (RE) in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus (T2DM)
Kapur, Anita
O'Connor-Semmes, Robin L.
Hussey, Elizabeth K.
Dobbins, Robert L.
Tao, Wenli
Hompesch, Marcus
Nunez, Derek J.
[J]. DIABETES, 2009, 58 : A136 - A136
[9] Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate (SGLT2 Inhibitor) and Metformin When Co-Administered in Type 2 Diabetes Mellitus (T2DM) Patients
Hussey, Elizabeth K.
Kapur, Anita
O'Connor-Semmes, Robin L.
Tao, Wenli
Poo, Jorge L.
Dobbins, Robert L.
[J]. DIABETES, 2009, 58 : A157 - A157
[10] Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2 (SGLT2), Reduces Serum Glucose in Type 2 Diabetes Mellitus (T2DM) Patients
Dobbins, Robert L.
Kapur, Anita
Kapitza, Christoph
O'Connor-Semmes, Robin L.
Tao, Wenli
Hussey, Elizabeth K.
[J]. DIABETES, 2009, 58 : A154 - A154

← 1 2 3 4 5 →